NCT01499563 - Study of a Novel Antipsychotic ITI-007 in Schizophrenia | Biotech Hunter

Enrollment

335

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

November 30, 2013

Conditions

Schizophrenia

Interventions

DRUG

ITI-007

Capsules containing ITI-007 for 28 days

DRUG

Placebo

Capsules containing inactive placebo for 28 days

DRUG

Risperidone

Capsules containing risperidone for 28 days

Trial Locations (8)

Clinical Site, Little Rock

Clinical Site, Garden Grove

Clinical Site, Atlanta

Clinical Site, Rockville

Clinical Site, St Louis

Clinical Site, Willingboro

Clinical Site, Philadelphia

Clinical Site, Austin